ACN Newswire
HONG KONG, Aug 2, 2025 – (ACN Newswire) – Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash. Upon completion of the subscription and inclusive of shares already held…
Read More
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies
Nancie Buresh
19:20
HONG KONG, Aug 2, 2025 – (ACN Newswire) – Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash. Upon completion of the subscription and inclusive of shares already held…
